文献速递艾滋病与性传播感染细菌感染、耐药与抗菌药物

TDF/FTC暴露前预防与HIV阴性青少年男性骨密度下降的内分泌机制

Decline in Bone Mass With Tenofovir Disoproxil Fumarate/Emtricitabine Is Associated With Hormonal Changes in the Absence of Renal Impairment When Used by HIV-Uninfected Adolescent Boys and Young Men for HIV Preexposure Prophylaxis.
PubMed 文献 · Clin Infect Dis · 2016-11-15

在101名HIV阴性年轻男男性行为者中开展每日TDF/FTC暴露前预防研究,高药物暴露组第4周甲状旁腺激素升高、FGF23下降,且无肾功能差异。第48周高暴露组全髋骨密度下降幅度更大,且与第4周TFV-DP和FGF23相关,提示内分泌 disruption 是TDF相关骨密度下降的主要因素。

要点

  • 高TDF/FTC暴露者第4周PTH升高、FGF23下降,肾功能指标无差异。
  • 第48周高暴露组全髋BMD下降幅度大于低暴露组。
  • 高暴露组BMD下降与第4周TFV-DP负相关、与FGF23正相关。

核心结论

  • TDF/FTC用于HIV阴性年轻男性暴露前预防短期肾脏安全性良好,内分泌 disruption(PTH-FGF23轴)是该人群TDF相关骨密度下降的主要contributor。

研究设计与样本

  • 在HIV阴性年轻男男性行为者中开展每日TDF/FTC暴露前预防研究,共101名参与者,中位年龄20岁(范围15至22岁)。
  • 根据红细胞内替诺福韦二磷酸(TFV-DP)水平将参与者分为高药物暴露组和低药物暴露组。
  • 测量基线与随访时PTH-维生素D-FGF23轴、肌酐及肾小管磷酸盐重吸收率(TRP)等血液和尿液指标,并探索其与骨密度变化的关系。

主要发现

  • 与低暴露组相比,高暴露组第4周PTH较基线升高、FGF23下降,肌酐、磷酸盐和TRP无差异。

临床怎么用

  • 对使用TDF/FTC暴露前预防的HIV阴性青少年及年轻男性,应关注骨密度变化,短期肾功能监测可能不足以反映骨毒性风险。
  • PTH-FGF23轴变化或可作为TDF相关骨密度下降的早期提示指标,但需进一步验证。

局限性

  • 研究样本为HIV阴性年轻男男性行为者,结论外推至其他人群需谨慎。
  • 随访至48周,缺乏长期骨密度和骨折结局数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: We aimed to define the relative importance of renal and endocrine changes in tenofovir disoproxil fumarate (TDF)-related bone toxicity. METHODS: In a study of daily TDF/emtricitabine (FTC) preexposure prophylaxis (PrEP) in human immunodeficiency virus (HIV)-uninfected young men who have sex with men, we measured changes from baseline in blood and urine markers of the parathyroid hormone (PTH)-vitamin D-fibroblast growth factor 23 (FGF23) axis, creatinine, and renal tubular reabsorption of phosphate (TRP). We explored the relationship of those variables to changes in bone mineral density (BMD). Tenofovir-diphosphate (TFV-DP) in red blood cells was used to categorize participants into high and low drug exposure groups. RESULTS: There were 101 participants, median age 20 years (range 15 to 22). Compared with low drug exposure, high-exposure participants showed increase from baseline in PTH and decline in FGF23 by study week 4, with no differences in creatinine, phosphate, or TRP. At 48 weeks, the median (interquartile range) percent decline in total hip BMD was greater in those with high- compared to low- exposure (-1.59 [2.77] vs +1.54 [3.34] %, respectively; P = .001); in high-exposure participants, this correlated with week 4 TFV-DP (inversely; r = -0.60, P = .002) and FGF23 (directly; r = 0.42; P = .039) but not other variables. CONCLUSIONS: These findings support the short-term renal safety of TDF/FTC PrEP in HIV-seronegative young men and suggest that endocrine disruption (PTH-FGF23) is a primary contributor to TDF-associated BMD decline in this age group. CLINICAL TRIALS REGISTRATION: NCT01769469.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Havens PL, Stephensen CB, Van Loan MD, et al. Decline in Bone Mass With Tenofovir Disoproxil Fumarate/Emtricitabine Is Associated With Hormonal Changes in the Absence of Renal Impairment When Used by HIV-Uninfected Adolescent Boys and Young Men for HIV Preexposure Prophylaxis. Clin Infect Dis. 2016. PMID: 28013265. doi:10.1093/cid/ciw765

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。